Timothy J. Brown, Peifeng Ruan, Amy Little Jones, Nilesh Verma, Matthew R. Porembka, Shahed Badiyan, Sam C. Wang, Nina Niu Sanford, Syed Mohammad Ali Kazmi. "FOLFIRI-ramucirumab (FOLFIRI-Ram) versus ramucirumab-paclitaxel (Ram-Pac) in the second line (2L) for patients with advanced upper gastrointestinal (UGI) cancer: A real-world propensity-score matched analysis of survival.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.4_suppl.377